Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The management of severe/prolonged SARS-CoV-2 infections in immunocompromised hosts is still challenging. We describe nine patients with hematologic malignancies with a history of unsuccessful SARS-CoV-2 treatment receiving antiviral combination treatment for persistent infection at a tertiary hospital in central Italy (University Hospital of Careggi, Florence). Combination treatments consisted of nirmatrelvir/ritonavir plus molnupiravir ( = 4), nirmatrelvir/ritonavir plus remdesivir ( = 4) or remdesivir plus molnupiravir ( = 1) for 10 days, in some cases associated with sotrovimab. Combinations were generally well tolerated. One patient obtained viral clearance but died due to the underlying disease. In eight cases, clinical and virological success was confirmed by radiological follow-up. Antivirals combination is likely to become a mainstay in the future management of COVID-19 among immunocompromised patients, but knowledge in this field is still very limited and prospective studies on larger cohorts are urgently warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1120009X.2024.2367935 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024.
J Viral Hepat
October 2025
Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.
View Article and Find Full Text PDFPharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection.
Liver Int
October 2025
Department of Pediatrics and Clinical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Background And Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low- and middle-income countries. WHO guidelines recommend a half-adult dose for children (14-25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17-35 kg.
View Article and Find Full Text PDFTargeted discovery of sesquiterpene indole alkaloids from Greenwayodendron suaveolens.
Phytochemistry
September 2025
Équipe "Chimie des substances naturelles" BioCIS, CNRS, Université Paris-Saclay, 17, avenue des Sciences, 91400, Orsay, France. Electronic address:
Throughout the past decades, annonaceous plants have been of particular interest to the natural product community because of their therapeutic value and their richness in isoquinoline alkaloids. Taking advantage from our laboratory historical collection of these compounds, a MS/MS database of 322 isoquinolines and other metabolites from Annonaceae was implemented and named IQAMDB . The present report describes the dereplication of known alkaloids from stem barks of Greenwayodendron suaveolens (Engl.
View Article and Find Full Text PDFActivity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study.
Infect Dis (Lond)
September 2025
Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy.
Background: The combination of antivirals and monoclonal antibodies (mAbs) in the first phase of COVID-19 has demonstrated to reduce time to viral clearance, but the superiority of combination compared to antiviral monotherapy is still debated.
Research Design And Methods: In an observational, prospective study, we enrolled immunocompromised outpatients with mild-to-moderate COVID-19 treated with one antiviral monotherapy within 7 days from symptoms onset, with or without sotrovimab from January 1, 2024 to October 31, 2024, and we compared them to an identical cohort of patients treated with a combination of one antiviral and sotrovimab, from May 1, 2023 to December 30, 2023. 1st of May 2023 and 31st of October 2024.
Combined neoadjuvant chemotherapy and immunotherapy in a hepatitis B virus-positive patient with locally advanced rectal adenocarcinoma: a case report and literature review.
Front Oncol
August 2025
Department of Surgical Oncology, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, Guangdong, China.
Microsatellite-stable (MSS) rectal adenocarcinoma remains a therapeutic challenge, particularly in patients with complicating factors such as chronic hepatitis B virus (HBV) infection. Advances in immunotherapy, including immune checkpoint inhibitors (ICIs), have introduced new opportunities to improve the treatment outcomes in this subset, yet their application in HBV-positive cancer patients is less well understood. Here we report the case of a 46-year-old female with MSS locally advanced rectal adenocarcinoma and active HBV infection, successfully treated with cmFOLFOXIRI combined with camrelizumab as neoadjuvant therapy.
View Article and Find Full Text PDF